Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealthPartners Part D Step Therapy Coverage Update…
    Ask Trek AI about this page
    CurrentHealthPartnersPolicy 26132

    2026 Medicare Part D Step Therapy Requirements

    Customize your policy alerts

    Sign up for HealthPartners Policy 26132 alerts

    Get alerted when Policy 26132 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Specifies Part D step therapy (prior use) requirements for certain branded and generic drug products on the HealthPartners Part D formulary; applies to Medicare Part D beneficiaries under the HealthPartners plan.

    Policy Summary
    PayerHealthPartners
    Policy2026 Medicare Part D Step Therapy Requirements
    Policy CodePolicy 26132
    Change TypeAnnual review — no material changes
    Effective DateAug 1, 2026
    Last ReviewJul 21, 2026
    Next Review DateJul 21, 2026
    Key ActionDocument prior use of the specified comparator product within the previous 12 months to establish eligibility for Step 2 coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2drug groups with step therapy rules listed
    12lookback period (months)
    08/01/2026policy effective

    Coverage Criteria

    RYTARY — Step 2 requirement

    Policy Summary
    PayerHealthPartners
    Policy2026 Medicare Part D Step Therapy Requirements
    Policy CodePolicy 26132
    Change TypeAnnual review — no material changes
    Effective DateAug 1, 2026
    Last ReviewJul 21, 2026
    Next Review DateJul 21, 2026
    Key ActionDocument prior use of the specified comparator product within the previous 12 months to establish eligibility for Step 2 coverage.
    SourceLink
    On This Page
    Coverage CriteriaCoding / Affected ProductsProvider Actions & DocumentationStep Therapy RulesDefinitionsBackground

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Covered when ALL of the following are met

    RYTARY (carbidopa-levodopa ER capsules) Step 2: Prior use of carbidopa-levodopa immediate-release OR extended-release tablets within the previous 12 months.12 months

    Applies to listed ER capsule strengths

    Tazarotene topical — Step 2 requirement

    Covered when ALL of the following are met

    Tazarotene topical products Step 2: Prior use of tazarotene 0.1% cream within the previous 12 months.12 months

    Applies to listed tazarotene topical formulations

    No explicit exclusions are listed in this policy document.

    The policy does not list any conditions that would render these products not medically necessary. Instead, coverage for the listed Step 2 products is contingent on prior-use (step therapy) requirements described in the criteria.

    Coding / Affected Products

    Affected RYTARY formulationsmixed
    CARBIDOPA ER 23.75 MG-LEVODOPA 95 MGcapsule, extended release (RYTARY product affected)
    CARBIDOPA ER 36.25 MG-LEVODOPA 145 MGcapsule, extended release
    CARBIDOPA ER 48.75 MG-LEVODOPA 195 MGcapsule, extended release
    CARBIDOPA ER 61.25 MG-LEVODOPA 245 MGcapsule, extended release
    Affected tazarotene topical productsmixed
    tazarotene 0.05% topical creamtopical cream
    tazarotene 0.05% topical geltopical gel
    tazarotene 0.1% topical geltopical gel
    inv-07: Prior-use lookback — within the previous 12 months
    Lookback periodPrior-use lookback: within the previous 12 months
    Applies toStep 2 products requiring prior comparator use (RYTARY ER capsules; tazarotene topical step-ups)
    Evidence requiredDocumentation must show prior use of the specified comparator product during the 12-month lookback
    ConsequenceFailure to document prior use within 12 months may result in step-therapy denial

    Provider Actions & Documentation

    Prior Authorization

    Prior-use required (12-month lookback)

    Prior use of the specified comparator product within the previous 12 months is required before coverage of the Step 2 products.

    Step Therapy

    Step 2 prior-use requirement (drug-specific)

    Coverage of Step 2 formulations requires documented prior use of the designated lower-step products: for RYTARY ER capsules, prior use of carbidopa-levodopa immediate‑release OR extended‑release tablets within the previous 12 months; for the listed tazarotene topical products, prior use of tazarotene 0.1% cream within the previous 12 months.

    • RYTARY: prior use of carbidopa‑levodopa immediate‑release or extended‑release tablets within the previous 12 months.
    • Tazarotene topical products: prior use of tazarotene 0.1% cream within the previous 12 months.
    Documentation Required

    Evidence of prior therapy required in request

    Documentation submitted for authorization must demonstrate prior use of the specified comparator therapy within the previous 12 months — e.g., evidence of use of immediate‑release or extended‑release carbidopa‑levodopa for RYTARY or tazarotene 0.1% cream for tazarotene topical products.

    • Show dates or records confirming use within the previous 12 months.
    • Specify which comparator product was used (immediate‑release vs extended‑release carbidopa‑levodopa; tazarotene 0.1% cream).
    Denial Risk

    Denial risk if prior use not documented

    Failure to document prior use of the specified comparator product within the previous 12 months may result in denial of coverage under the step therapy rules for the listed Step 2 products.

    Step Therapy Rules

    StepRequirementLookback period
    Step 2Prior documented use of the specified comparator product (for RYTARY: carbidopa-levodopa immediate‑release OR extended‑release tablets; for tazarotene topical products: tazarotene 0.1% cream) is required before coverage of the Step 2 products.12 months (within the previous 12 months)

    Definitions

    inv-13: Prior use — Documented use of the specified comparator product within the previous 12 months.
    DefinitionDocumented use of the specified comparator product within the previous 12 months
    Comparator for RYTARY Step 2Carbidopa-levodopa immediate-release OR extended-release tablets (prior use within 12 months required)
    Comparator for Tazarotene topical Step 2Tazarotene 0.1% cream (prior use within 12 months required)
    Required documentationClinical or pharmacy records demonstrating use of the named comparator product during the 12-month lookback period

    Background

    This policy sets Part D step therapy (prior-use) requirements for select formulary drugs. For the listed Step 2 products, coverage requires documented prior use of the designated comparator product within the previous 12 months (for example, prior use of carbidopa‑levodopa immediate‑release or extended‑release tablets for RYTARY formulations, or prior use of tazarotene 0.1% cream for listed tazarotene topical products). Documentation of that prior therapy must be provided to support coverage.